Aromatase in hyperplasia and carcinoma of the human prostate

The expression and activity of aromatase was evaluated in 19 individuals with benign prostatic hyperplasia (BPH) and 26 prostatic carcinoma (PC) patients to elucidate the possible biological significance of in situ estrogen production in the development of human prostatic disorders. Marked aromatase immunoreactivity was observed in proliferative stromal cells, especially those around hyperplastic glands in 18 (95%) BPH patients and in stromal cells surrounding carcinomatous glands in 18 (69%) PC patient specimens. The percentage of aromatase‐positive stromal cells did not differ between BPH and PC. No significant correlation was apparent between the percentage of aromatase‐positive cells and either the extent of carcinoma differentiation or surgical stage in the PC patients. Quantitation of aromatase activity by the [3H] water assay yielded values of 27.23 ± 6.87 and 26.52 ± 9.12 fmol/hr/mg of protein for BPH (nine patients) and PC (nine patients), respectively. Reverse transcriptase and polymerase chain reaction analysis revealed that the mean aromatase mRNA content was 1.671 ± 0.82 and 1.11 ± 0.51 attomole/ng of total RNA (tRNA) for BPH (seven patients) and PC (four patients), respectively. There were no significant differences in aromatase activity or aromatase mRNA concentration between PC and BPH. The alternative use of multiple exons 1 of the aromatase gene was also examined. Predominant aromatase gene transcripts contained exon 1b in three of four of PC specimens and two of three BPH specimens examined, in contrast to the use of exon 1d previously described in normal prostate. Unlike breast and endometrium, therefore, aromatase expression in human prostate was not associated with malignancy. However, overexpression of aromatase, possibly attributable to abnormal gene regulation, may result in estrogen production in situ and play a role in the induction or development of human prostatic disorders. Prostate 31:118–124, 1997. © 1997 Wiley‐Liss, Inc.

[1]  K. Kurth,et al.  Placebo Controlled Double-blind Study to Test the Efficacy of the Aromatase Inhibitor Atamestane in Patients with Benign Prostatic Hyperplasia not Requiring Operation , 1995 .

[2]  N. Harada,et al.  Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. , 1995, The American journal of pathology.

[3]  D. Miller,et al.  CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. , 1994, The Journal of clinical endocrinology and metabolism.

[4]  A. Panzeri,et al.  Novel aromatase and 5α-reductase inhibitors , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  N. Harada,et al.  Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. , 1994, Human pathology.

[6]  J. McLachlan,et al.  Developmental estrogenization and prostatic neoplasia , 1994, The Prostate.

[7]  N. Harada,et al.  Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  N. Harada,et al.  Ontogeny of aromatase messenger ribonucleic acid in mouse brain: fluorometrical quantitation by polymerase chain reaction. , 1992, Endocrinology.

[9]  N. Harada,et al.  Regulation of aromatase cytochrome P-450 (estrogen synthetase) transcripts in the quail brain by testosterone. , 1992, Brain research. Molecular brain research.

[10]  C. Mendelson,et al.  Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. , 1991, The Journal of biological chemistry.

[11]  J. Oesterling,et al.  Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. , 1991, The Journal of urology.

[12]  A. Brodie,et al.  Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism. , 1989, Cancer research.

[13]  J. Karr,et al.  The possibility of aromatization of androgen in human prostate. , 1987, Journal of steroid biochemistry.

[14]  C. Mendelson,et al.  Preparation and characterization of polyclonal and monoclonal antibodies against human aromatase cytochrome P-450 (P-450AROM), and their use in its purification. , 1985, Archives of biochemistry and biophysics.

[15]  F. Habib,et al.  Failure of human benign prostatic hyperplasia to aromatise testosterone. , 1982, Journal of steroid biochemistry.

[16]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[17]  Thompson Ea,et al.  Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. , 1974 .

[18]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[19]  N. Harada,et al.  Molecular and epidemiological analyses of abnormal expression of aromatase in breast cancer. , 1995, Pharmacogenetics.

[20]  L. Skoog,et al.  Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue , 1992, The Prostate.

[21]  M. Soloway,et al.  Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues , 1992, The Prostate.

[22]  B. Mobbs,et al.  Quantitation of cytosolic and nuclear estrogen and progesterone receptor in benign, untreated, and treated malignant human prostatic tissue by radioligand binding and enzyme‐immunoassays , 1990, The Prostate.

[23]  N. Harada.  Novel properties of human placental aromatase as cytochrome P-450: purification and characterization of a unique form of aromatase. , 1988, Journal of biochemistry.

[24]  N. Stone,et al.  Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia , 1986, The Prostate.